Sirtex Medical Achieves Landmark Results in Liver Cancer Treatment

Sirtex Medical announced pivotal 12-month results from the DOORwaY90 study, highlighting significant advancements in treating hepatocellular carcinoma (HCC) with Y-90 selective internal radiation therapy (SIRT). The U.S.-based study reported a remarkable 100% local tumor control and a best overall response rate of 99%, setting new benchmarks for Y-90 therapy in HCC patients.

This study underscores the potential of SIR-Spheres Y-90 resin microspheres to sustain tumor responses, with a high complete response rate of 90% and 75% of responses lasting beyond six months. Personalized dosimetry was key in maintaining stable liver function for over 95% of patients after 12 months.

Presented at the Society of Interventional Radiology Annual Meeting, these findings suggest radioembolization as a promising liver-directed treatment. Sirtex CEO Matt Schmidt expressed confidence in these outcomes, emphasizing the future possibilities for treatment using SIR-Spheres.